

**CLAIMS**


1. A peptide having a structure selected from the group consisting of:




,




,




,



NH2
O
N
O
NH
O
NH2
HO
HN
O
NH
O
O
HN
O
NH
O
NH
O
NH
O
NH
O
NH2
HN
NH
O
HN
O
HN
O
S
S
NH
NH2
O
O
NH
H
OH
O
HN
O
N
H
NH
O
O
HN
HN
O
O
N+

,





,


HO
O
H
HN
O
H
N
O
NH
HN
O
O
NH
4
HN
O
N
O
NH2
N
O
HN
O
NH
O
N+
HN
N
H
S
S
NH
H
O
NH
HN
O
O
H
N
O
O
NH
HN
O
O
NH2
N
H
O
O
OH
,




,



,




,




,




,



,




, and



,


or a pharmaceutically acceptable salt thereof.

2. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

3. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

4. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

5. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

6. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

7. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

8. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

9. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

10. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

11. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

12. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

13. The peptide of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

14. The peptide of claim 1, having the following structure:



or a pharmaceutically acceptable salt thereof.

15. The peptide of claim 1, having the following structure:



or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the peptide of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. Use of the peptide of claim 1 in the manufacture of a medicament for treating a disease or disorder associated with Interleukin 23 (IL-23)/Interleukin 23 Receptor (IL-23R), wherein a therapeutically effective amount of the peptide is to be administered to a subject in need thereof.

18. The use of claim 17, wherein the disease or disorder is selected from multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, Celiac disease (nontropical Sprue), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, enteropathy associated with seronegative arthropathies, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

19. The use of claim 17, wherein the disease or disorder is selected from ulcerative colitis (UC), Crohn's disease (CD), psoriasis (PsO), or psoriatic arthritis (PsA).

20. The peptide of claim 1 for use in the treatment of a disease or disorder associated with Interleukin 23 (IL-23)/Interleukin 23 Receptor (IL-23R), wherein a therapeutically effective amount of the peptide is to be administered to a subject in need thereof.